EUVIMEDEUVIMED entdecken
Studienprotokoll

Clinical Characteristics, Treatment Response, and Outcomes of Bronchiolitis Obliterans Syndrome in Children with Hematologic Malignancies Undergoing Haploidentical Hematopoietic Cell Transplantation with Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin-Based Protocol: A Single-Center Study

Feng Zhang, Guan-Hua Hu, Pan Suo, Lu Bai, Ying-Xi Zuo, Hui-Fang Wang, Lan-Ping Xu, Yu Wang, Jun Kong, Xiao-Dong Mo, Chen-Hua Yan, Feng-Rong Wang und 7 weitere

Transplantation and Cellular Therapy · 2026

DOI: 10.1016/j.jtct.2025.09.047 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Transplantation and Cellular Therapy, 2026. Verfasst von Feng Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Bronchiolitis Obliterans, Hematopoietic Stem Cell Transplantation, Antilymphocyte Serum, Hematologic Neoplasms. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Peking University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited data are available on bronchiolitis obliterans syndrome (BOS) in children undergoing haploidentical hematopoietic cell transplantation (haplo-HCT). To describe the clinical characteristics, treatment response, and factors influencing first-line treatment response in BOS patients undergoing haplo-HCT using a granulocyte colony-stimulating factor/antithymocyte globulin-based protocol. We conducted a single-center retrospective study including 60 pediatric patients with BOS at Peking University People's Hospital between January 2016 and December 2022. BOS was diagnosed at a median of 12.85 (interquartile range: 10.52 to 16.82) mo after haplo-HCT, and patients were followed for a median of 28.4 (95% confidence interval [CI]: 22.9 to 37.8) mo from BOS diagnosis. Among the 52 evaluable patients with long-term follow-up, the overall response rate (ORR) for first-line treatment was 33%. For 15 evaluable patients receiving second-line treatment, the ORR was 13%, resulting in a total ORR of 46% across first-line and second-line therapy. Three significant independent predictors of first-line treatment response were identified: NIH lung score 3 at baseline (odds ratio [OR], 0.112; 95% CI, 0.014 to 0.866; P = .036), disease status of greater than or equal to second complete remission at haplo-HCT (OR, 0.034; 95% CI, 0.002 to 0.488; P = .013), and a duration of ≥12.85 mo from haplo-HCT to BOS diagnosis (OR, 9.890; 95% CI, 1.725 to 56.692; P = .010). Pulmonary function trajectories showed that patients with baseline NIH lung scores of 2 or 3 experienced a more pronounced decline in percent of predicted FEV1 after BOS diagnosis compared to those with a score of 1. These findings highlight the importance of early diagnosis of BOS and initiating treatment for patients with early stages of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchiolitis ObliteransHematopoietic Stem Cell TransplantationAntilymphocyte SerumHematologic NeoplasmsGranulocyte Colony-Stimulating FactorTransplantation, HaploidenticalHumansMaleFemaleChildRetrospective StudiesTreatment OutcomeChild, PreschoolAdolescentInfantBronchiolitis Obliterans Syndrome

Stichwörter der Autor:innen

Bronchiolitis obliterans syndromeHematopoietic cell transplantationPediatrics

Substanzen

Antilymphocyte SerumGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking Univer…

Förderung

  • Peking University

Zitieren

APA

Zhang, F., Hu, G. H., Suo, P., Bai, L., Zuo, Y. X., Wang, H. F., Xu, L. P., Wang, Y., Kong, J., Mo, X. D., Yan, C. H., Wang, F. R., Zheng, F. M., Wang, Z. D., Sun, Y. Q., Liu, K. Y., Zhang, X. H., Huang, X. J., & Cheng, Y. F. (2026). Clinical Characteristics, Treatment Response, and Outcomes of Bronchiolitis Obliterans Syndrome in Children with Hematologic Malignancies Undergoing Haploidentical Hematopoietic Cell Transplantation with Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin-Based Protocol: A Single-Center Study. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2025.09.047

Vancouver

Zhang F, Hu GH, Suo P, Bai L, Zuo YX, Wang HF, et al. Clinical Characteristics, Treatment Response, and Outcomes of Bronchiolitis Obliterans Syndrome in Children with Hematologic Malignancies Undergoing Haploidentical Hematopoietic Cell Transplantation with Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin-Based Protocol: A Single-Center Study. Transplantation and Cellular Therapy. 2026. doi:10.1016/j.jtct.2025.09.047

BibTeX
@article{Zhang2026,
  author = {Zhang, Feng and Hu, Guan-Hua and Suo, Pan and Bai, Lu and Zuo, Ying-Xi and Wang, Hui-Fang and Xu, Lan-Ping and Wang, Yu and Kong, Jun and Mo, Xiao-Dong and Yan, Chen-Hua and Wang, Feng-Rong and Zheng, Feng-Mei and Wang, Zhi-Dong and Sun, Yu-Qian and Liu, Kai-Yan and Zhang, Xiao-Hui and Huang, Xiao-Jun and Cheng, Yi-Fei},
  title = {Clinical Characteristics, Treatment Response, and Outcomes of Bronchiolitis Obliterans Syndrome in Children with Hematologic Malignancies Undergoing Haploidentical Hematopoietic Cell Transplantation with Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin-Based Protocol: A Single-Center Study},
  journal = {Transplantation and Cellular Therapy},
  year = {2026},
  doi = {10.1016/j.jtct.2025.09.047}
}
Kostenlos starten →